Tenaya Therapeutics (TNYA) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Tenaya Therapeutics (NASDAQ: TNYA):

• 3/14/2026 – Tenaya Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/12/2026 – Tenaya Therapeutics had its “outperform” rating reaffirmed by Leerink Partners. They now have a $2.00 price target on the stock.
• 3/12/2026 – Tenaya Therapeutics had its “outperform” rating reaffirmed by William Blair.
• 3/12/2026 – Tenaya Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $8.00 price target on the stock.
• 3/5/2026 – Tenaya Therapeutics was upgraded by Lifesci Capital to “strong-buy”.

Insider Buying and Selling at Tenaya Therapeutics

In related news, major shareholder Group Gp Lp Column III sold 3,511,826 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $0.56, for a total transaction of $1,966,622.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 8,594,047 shares of company stock valued at $5,430,207. Insiders own 48.65% of the company’s stock.

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.